CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Country • United States
    Entity • country not supported, please select another country
    English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文

    Trade Gilead Sciences - GILD CFD

    81.96
    1.47%
    0.15
    Low: 80.78
    High: 81.98
    Market Trading Hours* (UTC) Open now
    Closes on Friday at 21:00

    Mon - Thu: 08:10 - 00:00

    Fri: 08:10 - 21:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.15
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.024874 %
    Charges from borrowed part ($-0.99)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Go to platform
    		-0.024874%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.002651 %
    Charges from borrowed part ($0.11)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Go to platform
    		0.002651%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 20%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Gilead Sciences Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 80.79
    Open* 80.78
    1-Year Change* 35.51%
    Day's Range* 80.78 - 81.98
    52 wk Range 57.17-89.74
    Average Volume (10 days) 6.23M
    Average Volume (3 months) 127.95M
    Market Cap 101.52B
    P/E Ratio 22.34
    Shares Outstanding 1.25B
    Revenue 27.28B
    EPS 3.64
    Dividend (Yield %) 3.69049
    Beta 0.40
    Next Earnings Date Apr 26, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Mar 30, 2023 81.05 -0.17 -0.21% 81.22 82.08 80.58
    Mar 29, 2023 80.93 0.10 0.12% 80.83 81.89 80.23
    Mar 28, 2023 80.83 1.40 1.76% 79.43 81.04 78.35
    Mar 27, 2023 78.94 -1.04 -1.30% 79.98 80.90 78.61
    Mar 24, 2023 79.94 1.68 2.15% 78.26 80.31 78.12
    Mar 23, 2023 78.05 0.35 0.45% 77.70 78.86 75.94
    Mar 22, 2023 77.88 -0.26 -0.33% 78.14 79.30 77.59
    Mar 21, 2023 78.29 -0.99 -1.25% 79.28 79.96 78.29
    Mar 20, 2023 78.82 2.26 2.95% 76.56 79.59 76.14
    Mar 17, 2023 77.23 -2.28 -2.87% 79.51 79.78 76.46
    Mar 16, 2023 78.98 0.19 0.24% 78.79 79.88 77.74
    Mar 15, 2023 78.98 -0.65 -0.82% 79.63 79.82 78.03
    Mar 14, 2023 78.62 -0.12 -0.15% 78.74 79.83 78.24
    Mar 13, 2023 79.28 -0.26 -0.33% 79.54 81.19 76.94
    Mar 10, 2023 79.00 0.48 0.61% 78.52 80.24 77.61
    Mar 9, 2023 78.90 -0.83 -1.04% 79.73 80.58 78.22
    Mar 8, 2023 79.73 -0.36 -0.45% 80.09 80.68 79.48
    Mar 7, 2023 79.79 -0.94 -1.16% 80.73 81.23 79.79
    Mar 6, 2023 81.04 0.27 0.33% 80.77 81.25 80.35
    Mar 3, 2023 80.57 1.14 1.44% 79.43 81.09 79.03

    Gilead Sciences Events

    Time (UTC) Country Event
    No events scheduled
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 27281 27305 24689 22449 22127
    Revenue 27281 27305 24689 22449 22127
    Cost of Revenue, Total 5657 6601 4572 4675 4853
    Gross Profit 21624 20704 20117 17774 17274
    Total Operating Expense 19951 17387 20618 18162 13927
    Selling/General/Admin. Expenses, Total 5673 5246 5151 4381 4056
    Research & Development 5921 5540 10895 8934 4846
    Unusual Expense (Income) 2700 172 172
    Operating Income 7330 9918 4071 4287 8200
    Interest Income (Expense), Net Non-Operating -1592 -1611 -2684 227 -964
    Other, Net 76 -29 282 646 563
    Net Income Before Taxes 5814 8278 1669 5160 7799
    Net Income After Taxes 4566 6201 89 5364 5464
    Minority Interest 26 24 34 22 -5
    Net Income Before Extra. Items 4592 6225 123 5386 5459
    Net Income 4592 6225 123 5386 5455
    Income Available to Common Excl. Extra. Items 4592 6225 123 5386 5459
    Income Available to Common Incl. Extra. Items 4592 6225 123 5386 5455
    Dilution Adjustment
    Diluted Net Income 4592 6225 123 5386 5455
    Diluted Weighted Average Shares 1262 1262 1263 1277 1308
    Diluted EPS Excluding Extraordinary Items 3.63867 4.93265 0.09739 4.2177 4.17355
    Dividends per Share - Common Stock Primary Issue 2.92 2.84 2.72 2.52 2.28
    Diluted Normalized EPS 5.31889 4.93265 0.09739 4.30525 4.26568
    Total Extraordinary Items -4
    Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021
    Total revenue 7389 7042 6260 6590 7244
    Revenue 7389 7042 6260 6590 7244
    Cost of Revenue, Total 1396 1395 1442 1424 2627
    Gross Profit 5993 5647 4818 5166 4617
    Total Operating Expense 5122 4205 4231 6393 6304
    Selling/General/Admin. Expenses, Total 2020 1213 1357 1083 1650
    Research & Development 1706 1597 1432 1186 2027
    Unusual Expense (Income) 0 0 0 2700
    Operating Income 2267 2837 2029 197 940
    Interest Income (Expense), Net Non-Operating -287 -426 -545 -334 -181
    Other, Net 51 21 19 -15
    Net Income Before Taxes 2031 2432 1503 -152 759
    Net Income After Taxes 1633 1786 1135 12 376
    Minority Interest 7 3 9 7 6
    Net Income Before Extra. Items 1640 1789 1144 19 382
    Net Income 1640 1789 1144 19 382
    Income Available to Common Excl. Extra. Items 1640 1789 1144 19 382
    Income Available to Common Incl. Extra. Items 1640 1789 1144 19 382
    Diluted Net Income 1640 1789 1144 19 382
    Diluted Weighted Average Shares 1265 1261 1260 1262 1262
    Diluted EPS Excluding Extraordinary Items 1.29644 1.41872 0.90794 0.01506 0.30269
    Dividends per Share - Common Stock Primary Issue 0.73 0.73 0.73 0.73 0.71
    Diluted Normalized EPS 1.29644 1.41872 0.90794 1.40571 0.30269
    • Annual
    • Quarterly
    2021 2020 2019 2018 2017
    Total Current Assets 14772 15996 30296 35836 31823
    Cash and Short Term Investments 6520 7408 24352 30089 25510
    Cash & Equivalents 5338 5997 11631 17940 7588
    Short Term Investments 1182 1411 12721 12149 17922
    Total Receivables, Net 4493 4892 3582 3327 3851
    Accounts Receivable - Trade, Net 4493 4892 3582 3327 3851
    Total Inventory 1618 1683 922 814 801
    Prepaid Expenses 2141 2013 1403 1533 1649
    Total Assets 67952 68407 61627 63675 70283
    Property/Plant/Equipment, Total - Net 5663 5613 5170 4006 3295
    Goodwill, Net 8332 8108 4117 4117 4159
    Intangibles, Net 33455 33126 13786 15738 17100
    Long Term Investments 1309 502 1488 1423 11194
    Other Long Term Assets, Total 4421 5062 6770 2555 2712
    Total Current Liabilities 11610 11397 9759 10605 11635
    Accounts Payable 705 844 713 790 814
    Accrued Expenses 7600 7198 6254 6876 7271
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 1516 2757 2499 2748 2747
    Other Current Liabilities, Total 1789 598 293 191 803
    Total Liabilities 46883 50205 39102 42288 49841
    Total Long Term Debt 25179 28645 22094 24574 30795
    Long Term Debt 25179 28645 22094 24574 30795
    Minority Interest -5 19 125 147 59
    Other Liabilities, Total 5743 10144 7124 6962 7352
    Total Equity 21069 18202 22525 21387 20442
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Common Stock 1 1 1 1 1
    Additional Paid-In Capital 4661 3880 3051 2282 1264
    Retained Earnings (Accumulated Deficit) 16324 14381 19388 19024 19012
    Unrealized Gain (Loss) -4 2 1 -52 194
    Other Equity, Total 87 -62 84 132 -29
    Total Liabilities & Shareholders’ Equity 67952 68407 61627 63675 70283
    Total Common Shares Outstanding 1254 1254 1266 1282 1308
    Other Current Assets, Total 37 73 12
    Property/Plant/Equipment, Total - Gross 7556 7281 6592 5197 4289
    Accumulated Depreciation, Total -1893 -1668 -1422 -1191 -994
    Deferred Income Tax 4356
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    Total Current Assets 12629 14772 13991 13925 13278
    Cash and Short Term Investments 5325 6520 5738 6525 5666
    Cash & Equivalents 4296 5338 4362 4893 4065
    Short Term Investments 1029 1182 1376 1632 1601
    Total Receivables, Net 3787 4493 4566 4149 3925
    Accounts Receivable - Trade, Net 3787 4493 4566 4149 3925
    Total Inventory 1482 1618 1676 1772 1779
    Prepaid Expenses 2035 2141 2011 1479 1908
    Total Assets 63080 67952 67098 67984 67492
    Property/Plant/Equipment, Total - Net 5253 5121 5037 4996 4990
    Goodwill, Net 8314 8332 8332 8334 8334
    Intangibles, Net 30331 33455 33900 34341 34781
    Long Term Investments 1427 1309 1099 836 579
    Other Long Term Assets, Total 5126 4963 4739 5552 5530
    Total Current Liabilities 8558 11610 10245 10214 9705
    Accounts Payable 583 705 585 608 570
    Accrued Expenses 6483 7600 6702 6906 6661
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 1025 1516 2511 2261 2259
    Other Current Liabilities, Total 467 1789 447 439 215
    Total Liabilities 43153 46883 45628 48281 48540
    Total Long Term Debt 25183 25179 25175 27914 27907
    Long Term Debt 25183 25179 25175 27914 27907
    Deferred Income Tax 3687 4356 4603 4374 4464
    Minority Interest -12 -5 1 7 12
    Other Liabilities, Total 5737 5743 5604 5772 6452
    Total Equity 19927 21069 21470 19703 18952
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Common Stock 1 1 1 1 1
    Additional Paid-In Capital 4867 4661 4492 4271 4092
    Retained Earnings (Accumulated Deficit) 14986 16324 16903 15392 14821
    Unrealized Gain (Loss) -23 -4 -1 -1 0
    Other Equity, Total 96 87 75 40 38
    Total Liabilities & Shareholders’ Equity 63080 67952 67098 67984 67492
    Total Common Shares Outstanding 1255 1254 1255 1254 1254
    • Annual
    • Quarterly
    2021 2020 2019 2018 2017
    Net income/Starting Line 6201 89 5364 5460 4644
    Cash From Operating Activities 11384 8168 9144 8400 11898
    Cash From Operating Activities 329 288 255 226 233
    Amortization 1721 1192 1149 1203 1053
    Deferred Taxes -116 -214 -2098 289 -82
    Non-Cash Items 2760 8451 5272 2161 942
    Cash Taxes Paid 2509 2639 1793 3198 3342
    Cash Interest Paid 979 951 982 1070 1038
    Changes in Working Capital 489 -1638 -798 -939 5108
    Cash From Investing Activities -3131 -14615 -7817 14355 -16069
    Capital Expenditures -579 -650 -825 -924 -590
    Other Investing Cash Flow Items, Total -2552 -13965 -6992 15279 -15479
    Cash From Financing Activities -8877 770 -7634 -12318 3393
    Financing Cash Flow Items -145 -138 -122 -486 -330
    Total Cash Dividends Paid -3605 -3449 -3222 -2971 -2731
    Issuance (Retirement) of Stock, Net -377 -1327 -1540 -2611 -720
    Issuance (Retirement) of Debt, Net -4750 5684 -2750 -6250 7174
    Foreign Exchange Effects -35 43 -2 -85 137
    Net Change in Cash -659 -5634 -6309 10352 -641
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    Net income/Starting Line 12 6201 5825 3239 1722
    Cash From Operating Activities 1840 11384 8179 4926 2610
    Cash From Operating Activities 80 329 239 157 78
    Amortization 445 1721 1276 835 395
    Deferred Taxes -651 -116 243 3 71
    Non-Cash Items 3116 2760 1921 1564 753
    Changes in Working Capital -1162 489 -1325 -872 -409
    Cash From Investing Activities -1070 -3131 -2853 -2619 -2042
    Capital Expenditures -247 -579 -423 -284 -165
    Other Investing Cash Flow Items, Total -823 -2552 -2430 -2335 -1877
    Cash From Financing Activities -1794 -8877 -6935 -3408 -2477
    Financing Cash Flow Items -91 -145 -134 -95 -89
    Total Cash Dividends Paid -945 -3605 -2711 -1811 -917
    Issuance (Retirement) of Stock, Net -258 -377 -340 -252 -221
    Issuance (Retirement) of Debt, Net -500 -4750 -3750 -1250 -1250
    Foreign Exchange Effects -18 -35 -26 -3 -23
    Net Change in Cash -1042 -659 -1635 -1104 -1932
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 8.9207 111403199 -68465 2022-12-31 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 7.0154 87609319 3078449 2022-12-31 LOW
    Capital World Investors Investment Advisor 5.5167 68892972 11130228 2022-12-31 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.7198 58941373 -298977 2022-12-31 LOW
    Capital Research Global Investors Investment Advisor 4.3724 54602952 727482 2022-12-31 LOW
    Dodge & Cox Investment Advisor/Hedge Fund 2.8735 35885152 -484100 2022-12-31 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.9097 23848477 244886 2022-12-31 LOW
    Invesco Capital Management (QQQ Trust) Investment Advisor 1.307 16322394 84245 2023-02-28 LOW
    Fidelity Management & Research Company LLC Investment Advisor 1.2224 15265179 12533445 2022-12-31 LOW
    BlackRock Asset Management Ireland Limited Investment Advisor 1.1098 13859234 761084 2022-12-31 LOW
    Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 1.0402 12989939 -106202 2022-12-31 LOW
    Parnassus Investments, LLC Investment Advisor 0.9659 12062537 295282 2022-12-31 LOW
    Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 0.8558 10686823 -393685 2022-12-31 LOW
    BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund 0.7794 9733453 -126327 2022-12-31 LOW
    Amundi Asset Management, SAS Investment Advisor/Hedge Fund 0.7762 9693019 -93438 2022-12-31 HIGH
    Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.7521 9391729 -99918 2022-12-31 LOW
    Renaissance Technologies LLC Hedge Fund 0.7369 9202568 -820000 2022-12-31 HIGH
    Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.7185 8972729 -116113 2022-12-31 LOW
    California Public Employees' Retirement System Pension Fund 0.6911 8630001 -344541 2022-12-31 LOW
    Mellon Investments Corporation Investment Advisor/Hedge Fund 0.6779 8465274 -377056 2022-12-31 LOW

    Why choose Capital.com? Our numbers speak for themselves.

    Capital.com Group

    500K+

    Traders

    92K+

    Active clients monthly

    $53M+

    Monthly investing volume

    $30M+

    Withdrawn each month

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results
    Profit/Loss

    Gilead Company profile

    What is Gilead Sciences?

    Gilead Sciences Inc. is a US biopharmaceutical company. Following a series of mergers and acquisitions, Gilead is now one of the biggest players in its field with almost 9,000 employees working all over the globe. A portfolio of shipped products includes medicals for HIV treatment and HIV prevention. Gilead focuses on medical products that serve to cure oncology, liver diseases, cardiovascular disorders and many other severe health conditions. Gilead has a wide network of partnerships and collaborations.
     

    What does the company do?

    A research-based biopharmaceutical company, Gilead Sciences, discovers, produces and markets innovative healthcare products that are capable of transforming and simplifying medical care for people, who suffer from life-threatening diseases globally.

    The portfolio of Gilead’s products and investigational drugs includes innovative treatments for AIDS/HIV, cancer, respiratory, inflammatory, liver diseases and cardiovascular conditions.
     

    A bit of Gilead Sciences’ history

    Gilead Sciences was established in June 1987. The company primarily focused on antiviral medicines. It concentrated on gene therapy, estimating the potential of genetic code blockers. The development and research of small molecule antiviral therapeutics started in 1991 with licensing of a group of nucleotide compounds (tenofovir was one of them) that further became widely-used anti-retroviral medicines. In 1990, Gilead collaborated with Glaxo for the development and research of genetic code blockers, known as antisense.

     

    Who founded Gilead Sciences?

    Gilead Sciences was founded by Michael L. Riordan, a 29-year-old doctor, who graduated from the Johns Hopkins School of Medicine, Washington University of St. Louis and the Harvard Business School. Riordan worked as the company’s CEO from its inception till 1996.

     

    Establishing the company and its vision, Michael L. Riordan collaborated with three major scientific advisors, including Doug Melton of Harvard, Peter Dervan of Caltech and Harold Weintraub of the Fred Hutchinson Cancer Research Center.
     
    A venture capital firm Menlo Ventures, where Riordan worked for one year, made the first investment of $2 million into Gilead Sciences.
     

    Current size, team and locations

    Headquartered in Foster City, California, US, the company operates across 6 continents and has a team of almost 9,000 employees. Gilead has a portfolio of 24 marketed products and is rapidly expanding. The research and development division works on over 400 clinical studies, evaluating compounds that potentially will become the next generation of efficient medicines.

     

    Quick facts about Gilead Sciences

    • Developing access programmes to provide HIV and viral hepatitis medicines at significantly reduced prices in 134 low- and middle-income countries, the company serves approximately 10 million people in the developing world with Gilead’s HIV/AIDS therapies.
    • It is said that Riordan wanted to attract Warren Buffett as Gilead’s board member and investor, but was unsuccessful.
    • In 2005 the company created the Gilead Foundation, a non-profit organisation that is trying to improve the well-being and health of underserved communities in the United States and globally.
    • In 2016 the company gained $30.4 billion in revenue and was ranked the second in the Barron’s 500 rankings. The company also became the first in Business Insider’s list of top companies to work for.

    How to learn the Gilead Sciences share price?

    Gilead Sciences shares are listed and traded on the NASDAQ stock exchange under the ticker symbol GILD. The company is a component of the NASDAQ-100, S&P 500 and S&P 100 indices. Join Capital.com to trade CFDs on the Gilead Sciences share price fluctuations and follow the GILD chart in real-time.

    Industry: Pharmaceuticals (NEC)

    333 Lakeside Dr
    FOSTER CITY
    CALIFORNIA 94404-1147
    US

    Income Statement

    • Annual
    • Quarterly

    News

    A file photo shows a part of a stack of 500 Canadian gold coins, worth $1 million USD according to Sprott Money, is displayed at the precious metals dealer's booth at the Prospectors and Developers Association of Canada (PDAC) annual conference in Toronto

    PRECIOUS-Fed slowdown bets steer gold toward second quarterly rise

    Gold prices slipped on Friday, but the safe-haven metal was bound for its second straight quarterly rise after recent banking turmoil raised hopes of a less-aggressive U.S. Federal Reserve and shored up interest in bullion.

    09:37, 31 March 2023
    People use DBS automated teller machines (ATMs) in Singapore March 31, 2022.

    Singapore's DBS has seen inflows in SVB aftermath, CEO says

    DBS Group, Singapore's largest bank, has benefited from inflows amounting to a "few hundred millions" in the aftermath of the collapse of Silicon Valley Bank, its chief executive said on Friday.

    09:24, 31 March 2023
    Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., March 29, 2023.

    US STOCKS-Futures muted as investors await key inflation data

    U.S. stock index futures were flat on Friday as investors steered clear of big bets ahead of crucial inflation data, amid receding fears of a banking crisis.

    09:16, 31 March 2023
    A file photo of the logo of Australian energy company Origin pictured in Melbourne, Australia, July 3, 2016

    Asia M&As drop to decade low as tumultuous backdrop deters dealmaking

    Mergers and acquisitions (M&A) in the Asia-Pacific region fell to a decade low in the first three months of this year as a tumultuous geopolitical and macroeconomic environment left dealmakers cautious.

    09:14, 31 March 2023
    A file photo of a worker shoveling coal in a supply truck at a yard on the outskirts of Ahmedabad, India, October 25, 2018.

    Coal India surpasses annual output target for first time in 17 years

    Coal India Ltd said on Friday it had breached its annual production target of 700 million tonnes, the first time it had surpassed its goal since the fiscal year that ended in March 2006.

    09:13, 31 March 2023
    A file photo of bull and bear symbols in front of the German stock exchange in Frankfurt, Germany, February 12, 2019.

    Global IPOs marred by banks and recession enjoy few bright spots

    A banking crisis and worries of a recession have dampened the outlook for initial public offerings (IPOs) this year, prompting companies to slow down their plans to go public in what is likely to result in lower fees for investment banks.

    09:06, 31 March 2023
    A file photo of Unicredit Bank logo seen in this illustration taken March 12, 2023.

    UniCredit shareholders gather to vote on CEO's new pay scheme

    Shareholders in UniCredit met on Friday to vote on a new pay scheme for Chief Executive Andrea Orcel designed to reward outperformance with a 30% pay raise.

    09:04, 31 March 2023

    People also watch

    Gold

    1,978.06 Price
    -0.070% 1D Chg, %
    Long position overnight fee -0.0180%
    Short position overnight fee 0.0098%
    Overnight fee time 21:00 (UTC)
    Spread 0.30

    Oil - Crude

    75.43 Price
    +1.430% 1D Chg, %
    Long position overnight fee -0.0170%
    Short position overnight fee -0.0049%
    Overnight fee time 21:00 (UTC)
    Spread 0.03

    BTC/USD

    28,479.70 Price
    +1.390% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 60.00

    US100

    13,092.80 Price
    +1.000% 1D Chg, %
    Long position overnight fee -0.0249%
    Short position overnight fee 0.0027%
    Overnight fee time 21:00 (UTC)
    Spread 1.8

    Still looking for a broker you can trust?

    Join the 500.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading